<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>978</ReferenceId>
        <DateLastUpdated>2020-10-11-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11854201</PubmedId>
            <Abstract>Ganglioside mimicry in the lipopolysaccharide (LPS) fraction of Campylobacter jejuni isolated from Guillain-Barré syndrome (GBS) and Miller Fisher syndrome (MFS) patients was compared with isolates from patients with an uncomplicated enteritis. The antibody response to C. jejuni LPS and gangliosides in neuropathy patients and controls was compared as well. LPS from GBS and MFS-associated isolates more frequently contained ganglioside-like epitopes compared to control isolates. Almost all neuropathy patients showed a strong antibody response against LPS and multiple gangliosides in contrast to enteritis patients. Isolates from GBS patients more frequently had a GM1-like epitope than isolates from MFS patients. GQ1b-like epitopes were present in all MFS-associated isolates and was associated with anti-GQ1b antibody reactivity and the presence of oculomotor symptoms. These results demonstrate that the expression of ganglioside mimics is a risk factor for the development of post-Campylobacter neuropathy. This study provides additional evidence for the hypothesis that the LPS fraction determines the antiganglioside specificity and clinical features in post-Campylobacter neuropathy patients.</Abstract>
            <ArticleYear>2002</ArticleYear>
            <ArticlePages>1202-8</ArticlePages>
            <ArticleTitle>Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Ang</LastName>
                    <ForeName>C W</ForeName>
                </Author>
                <Author>
                    <LastName>Laman</LastName>
                    <ForeName>J D</ForeName>
                </Author>
                <Author>
                    <LastName>Willison</LastName>
                    <ForeName>H J</ForeName>
                </Author>
                <Author>
                    <LastName>Wagner</LastName>
                    <ForeName>E R</ForeName>
                </Author>
                <Author>
                    <LastName>Endtz</LastName>
                    <ForeName>H P</ForeName>
                </Author>
                <Author>
                    <LastName>De Klerk</LastName>
                    <ForeName>M A</ForeName>
                </Author>
                <Author>
                    <LastName>Tio-Gillen</LastName>
                    <ForeName>A P</ForeName>
                </Author>
                <Author>
                    <LastName>Van den Braak</LastName>
                    <ForeName>N</ForeName>
                </Author>
                <Author>
                    <LastName>Jacobs</LastName>
                    <ForeName>B C</ForeName>
                </Author>
                <Author>
                    <LastName>Van Doorn</LastName>
                    <ForeName>P A</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Neurology, Erasmus University/Academic Hospital Dijkzigt Rotterdam, Rotterdam, The Netherlands. Ang@bacl.azr.nl.</Affiliations>
            <ArticleChemicalList>Antibodies, Bacterial;Gangliosides;Lipopolysaccharides</ArticleChemicalList>
            <ArticleMeshHeadingsList>Antibodies, Bacterial(blood); Bacterial Typing Techniques; Campylobacter Infections(complications); Campylobacter jejuni(chemistry; classification; immunology); Carbohydrate Sequence; Gangliosides(immunology); Guillain-Barre Syndrome(etiology; microbiology); Humans; Lipopolysaccharides(chemistry; immunology); Miller Fisher Syndrome(etiology; microbiology); Molecular Mimicry; Molecular Sequence Data; Serotyping</ArticleMeshHeadingsList>
            <Journal>
                <Volume>70</Volume>
                <Issue>3</Issue>
                <Title>Infection and immunity</Title>
                <Issn>0019-9567</Issn>
                <MedlineTa>Infect Immun</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>GA1</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:27938</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>138830</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953577</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12889</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Miller-Fisher symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms, had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection, or had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>25</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27938</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953742</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12889</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Miller-Fisher symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms, had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection, or had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>25</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27938</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953574</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>8</NumberOfSubjectsResponded>
                            <ResponseFrequency>66.7</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27938</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953619</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:0060499</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained from cloning PBMCs of a patient with multifocal motor neuropathy, as described in Paterson et al, J Immunol. 1995 155:3049 [PMID:7673721].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <AssayComments>The epitope-specific antibody cross-reacted with ganglioside GD1b, which is a disialylated version of the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>WO1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other Structure from Source Organism</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28175</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953616</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:0060499</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained from cloning PBMCs of a patient with multifocal motor neuropathy, as described in Paterson et al, J Immunol. 1995 155:3049 [PMID:7673721].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAbs cross-reacted with C. jejuni LPS from the Penner O:19 serotype (strain CCUG 10950, a.k.a ATCC 43446), known to contain a carbohydrate region identical to part of this ganglioside carbohydrate region.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>WO1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Structurally Related</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:16412</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>10000691</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953617</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:0060499</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained from cloning PBMCs of a patient with multifocal motor neuropathy, as described in Paterson et al, J Immunol. 1995 155:3049 [PMID:7673721].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>WO1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27938</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953741</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27938</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953618</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:0060499</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained from cloning PBMCs of a patient with multifocal motor neuropathy, as described in Paterson et al, J Immunol. 1995 155:3049 [PMID:7673721].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <AssayComments>The epitope-specific antibody cross-reacted with ganglioside GM1, which is a sialylated version of the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>WO1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other Structure from Source Organism</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:61048</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GM1</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:61048</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>142077</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953578</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:61048</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953579</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12889</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Miller-Fisher symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms, had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection, or had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:61048</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953744</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12889</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Miller-Fisher symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms, had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection, or had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:61048</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953599</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>29 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:0060499</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained from cloning PBMCs of a patient with multifocal motor neuropathy, conduction block  and anti-epitope serum antibodies, as described in Willison et al, Ann Neurol. 1994 35:471 [PMID:8154875].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Sm1 (SM-1)</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:61048</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953600</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>29 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:0060499</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained from cloning PBMCs of a patient with multifocal motor neuropathy, conduction block  and anti-epitope serum antibodies, as described in Willison et al, Ann Neurol. 1994 35:471 [PMID:8154875].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAbs cross-reacted with C. jejuni LPS from the Penner O:19 serotype (strain CCUG 10950, a.k.a ATCC 43446), known to contain a carbohydrate region identical to part of this ganglioside carbohydrate region.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Sm1 (SM-1)</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Structurally Related</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:16412</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>10000691</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953743</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>25</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:61048</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GM2</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:51013</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>143251</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953746</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12889</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Miller-Fisher symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms, had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection, or had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:51013</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953745</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:51013</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953583</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>8.3</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:51013</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953584</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12889</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Miller-Fisher symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms, had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection, or had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:51013</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GD1a</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:18163</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>139429</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953747</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12889</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Miller-Fisher symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms, had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection, or had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:18163</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953748</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:18163</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953585</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12889</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Miller-Fisher symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms, had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection, or had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:18163</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953586</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>8.3</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:18163</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GD1b</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:28175</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>138831</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953749</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>8.3</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28175</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953587</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28175</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953588</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12889</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Miller-Fisher symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms, had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection, or had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28175</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GD3</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:28424</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>139967</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953751</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12889</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Miller-Fisher symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms, had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection, or had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28424</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953750</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>8.3</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28424</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953589</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>25</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28424</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953696</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000038</OrganismId>
                                <Sex>M</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <AccessionNonSequenceMolecule>
                                            <ChemicalType>Glycolipid</ChemicalType>
                                            <Molecule>
                                                <ChEBIId>CHEBI:16412</ChEBIId>
                                            </Molecule>
                                            <SourceOrganismId>10000701</SourceOrganismId>
                                        </AccessionNonSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>C. jejuni OH4384 (O19 serostrain)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50 ug LPS in CFA and boosts of 50 ug LPS in IFA on days 14, 28, and 42. One final dose in PBS was given 3 d. before fusion.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained as described in Goodyear et al, J Clin Invest. 1999 104:697 [PMID:10491405].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <AssayComments>The epitope-specific antibody cross-reacted with ganglioside GQ1b, which contains the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>CGM3</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other Structure from Source Organism</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27515</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953590</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12889</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Miller-Fisher symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms, had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection, or had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28424</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953694</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000038</OrganismId>
                                <Sex>M</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <AccessionNonSequenceMolecule>
                                            <ChemicalType>Glycolipid</ChemicalType>
                                            <Molecule>
                                                <ChEBIId>CHEBI:16412</ChEBIId>
                                            </Molecule>
                                            <SourceOrganismId>10000701</SourceOrganismId>
                                        </AccessionNonSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>C. jejuni OH4384 (O19 serostrain)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50 ug LPS in CFA and boosts of 50 ug LPS in IFA on days 14, 28, and 42. One final dose in PBS was given 3 d. before fusion.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained as described in Goodyear et al, J Clin Invest. 1999 104:697 [PMID:10491405].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>CGM3</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28424</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953695</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000038</OrganismId>
                                <Sex>M</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <AccessionNonSequenceMolecule>
                                            <ChemicalType>Glycolipid</ChemicalType>
                                            <Molecule>
                                                <ChEBIId>CHEBI:16412</ChEBIId>
                                            </Molecule>
                                            <SourceOrganismId>10000701</SourceOrganismId>
                                        </AccessionNonSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>C. jejuni OH4384 (O19 serostrain)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50 ug LPS in CFA and boosts of 50 ug LPS in IFA on days 14, 28, and 42. One final dose in PBS was given 3 d. before fusion.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained as described in Goodyear et al, J Clin Invest. 1999 104:697 [PMID:10491405].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAbs cross-reacted moderately with C. jejuni LPS from the Penner O:10 serotype (strain CCUG 10943, a.k.a ATCC 43438), known to share the alpha-N-acetylneuraminosyl-(2-&gt;8)-alpha-N-acetylneuraminosyl-(2-&gt;3)-beta-D-galactosyl- moiety with this ganglioside.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>CGM3</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Structurally Related</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:16412</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>10000698</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953625</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Sex>F</Sex>
                                <Age>67 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:5213</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained from cloning EBV-trasnformed PBMCs of a patient with chronic demyelinating peripheral neuropathy comprising severe sensory ataxia, areflexia and mild limb weakness interspersed with acute relapsing episodes of increasing limb weakness and craniobulbar dysfunction (including opthalmoplegia), as described in Willison et al, J Clin Invest. 1996 97:1155 [PMID:8636426].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAbs cross-reacted moderately with C. jejuni LPS from the Penner O:10 serotype (strain CCUG 10943, a.k.a ATCC 43438), known to share the alpha-N-acetylneuraminosyl-(2-&gt;8)-alpha-N-acetylneuraminosyl-(2-&gt;3)-beta-D-galactosyl- moiety with this ganglioside.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Ha1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Structurally Related</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:16412</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>10000698</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953627</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Sex>F</Sex>
                                <Age>67 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:5213</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained from cloning EBV-trasnformed PBMCs of a patient with chronic demyelinating peripheral neuropathy comprising severe sensory ataxia, areflexia and mild limb weakness interspersed with acute relapsing episodes of increasing limb weakness and craniobulbar dysfunction (including opthalmoplegia), as described in Willison et al, J Clin Invest. 1996 97:1155 [PMID:8636426].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <AssayComments>The epitope-specific antibody cross-reacted with ganglioside GQ1b, which contains the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Ha1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other Structure from Source Organism</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27515</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4, Figure 3</LocationOfData>
                        <BCellId>1953621</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Sex>F</Sex>
                                <Age>67 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:5213</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained from cloning EBV-trasnformed PBMCs of a patient with chronic demyelinating peripheral neuropathy comprising severe sensory ataxia, areflexia and mild limb weakness interspersed with acute relapsing episodes of increasing limb weakness and craniobulbar dysfunction (including opthalmoplegia), as described in Willison et al, J Clin Invest. 1996 97:1155 [PMID:8636426].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAbs cross-reacted weakly with C. jejuni LPS from the Penner O:19 serotype (strain CCUG 10950, a.k.a ATCC 43446), known to share the alpha-N-acetylneuraminosyl-(2-&gt;3)-beta-D-galactosyl- moiety with this ganglioside. It is also shown to differentially react with LPS obtained from C. jejuni isolates obtained from Guillain-Barre or Miller-Fisher syndromes, or from uncomplicated C. jejuni enteritis, as the mean reactivity is higher towards LPS obtained from Miller-Fisher patients samples than from the other two groups.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Ha1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Structurally Related</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:16412</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>10000691</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953622</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Sex>F</Sex>
                                <Age>67 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:5213</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained from cloning EBV-trasnformed PBMCs of a patient with chronic demyelinating peripheral neuropathy comprising severe sensory ataxia, areflexia and mild limb weakness interspersed with acute relapsing episodes of increasing limb weakness and craniobulbar dysfunction (including opthalmoplegia), as described in Willison et al, J Clin Invest. 1996 97:1155 [PMID:8636426].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Ha1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28424</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953624</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Sex>F</Sex>
                                <Age>67 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:5213</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained from cloning EBV-trasnformed PBMCs of a patient with chronic demyelinating peripheral neuropathy comprising severe sensory ataxia, areflexia and mild limb weakness interspersed with acute relapsing episodes of increasing limb weakness and craniobulbar dysfunction (including opthalmoplegia), as described in Willison et al, J Clin Invest. 1996 97:1155 [PMID:8636426].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                            <AssayComments>The epitope-specific antibody moderately cross-reacted with ganglioside GD1a.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Ha1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other Structure from Source Organism</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:18163</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953623</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Sex>F</Sex>
                                <Age>67 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:5213</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained from cloning EBV-trasnformed PBMCs of a patient with chronic demyelinating peripheral neuropathy comprising severe sensory ataxia, areflexia and mild limb weakness interspersed with acute relapsing episodes of increasing limb weakness and craniobulbar dysfunction (including opthalmoplegia), as described in Willison et al, J Clin Invest. 1996 97:1155 [PMID:8636426].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-High</QualitativeMeasurement>
                            <AssayComments>The epitope-specific antibody cross-reacted with ganglioside GD1b, which contains the epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Ha1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Lambda</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other Structure from Source Organism</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28175</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GQ1b</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Glycolipid</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:27515</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>130673</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953752</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27515</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953739</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000038</OrganismId>
                                <Sex>M</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <AccessionNonSequenceMolecule>
                                            <ChemicalType>Glycolipid</ChemicalType>
                                            <Molecule>
                                                <ChEBIId>CHEBI:16412</ChEBIId>
                                            </Molecule>
                                            <SourceOrganismId>10000701</SourceOrganismId>
                                        </AccessionNonSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>C. jejuni OH4384 (O19 serostrain)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50 ug LPS in CFA and boosts of 50 ug LPS in IFA on days 14, 28, and 42. One final dose in PBS was given 3 d. before fusion.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained as described in Goodyear et al, J Clin Invest. 1999 104:697 [PMID:10491405].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAbs cross-reacted weakly with C. jejuni LPS from the Penner O:10 serotype (strain CCUG 10943, a.k.a ATCC 43438), known to share the alpha-N-acetylneuraminosyl-(2-&gt;8)-alpha-N-acetylneuraminosyl-(2-&gt;3)-beta-D-galactosyl- moiety with this ganglioside.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>EG1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG3</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Structurally Related</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:16412</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>10000698</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953740</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000038</OrganismId>
                                <Sex>M</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <AccessionNonSequenceMolecule>
                                            <ChemicalType>Glycolipid</ChemicalType>
                                            <Molecule>
                                                <ChEBIId>CHEBI:16412</ChEBIId>
                                            </Molecule>
                                            <SourceOrganismId>10000701</SourceOrganismId>
                                        </AccessionNonSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>C. jejuni OH4384 (O19 serostrain)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50 ug LPS in CFA and boosts of 50 ug LPS in IFA on days 14, 28, and 42. One final dose in PBS was given 3 d. before fusion.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained as described in Goodyear et al, J Clin Invest. 1999 104:697 [PMID:10491405].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <AssayComments>The epitope-specific antibody cross-reacted weakly with ganglioside GD3, which contains a single instance of the alpha-N-acetylneuraminosyl-(2-&gt;8)-alpha-N-acetylneuraminosyl-(2-&gt;3)-beta-D-galactosyl, as compared to this epitope.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>EG1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG3</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Other Structure from Source Organism</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:28424</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953753</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12889</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Miller-Fisher symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms, had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection, or had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>25</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27515</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953592</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12842</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Guillain-Barre symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms. All but two neuropathy patients had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection. One of the remaining two patients had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>12</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>16.7</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27515</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 4</LocationOfData>
                        <BCellId>1953738</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000038</OrganismId>
                                <Sex>M</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <AccessionNonSequenceMolecule>
                                            <ChemicalType>Glycolipid</ChemicalType>
                                            <Molecule>
                                                <ChEBIId>CHEBI:16412</ChEBIId>
                                            </Molecule>
                                            <SourceOrganismId>10000701</SourceOrganismId>
                                        </AccessionNonSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>C. jejuni OH4384 (O19 serostrain)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50 ug LPS in CFA and boosts of 50 ug LPS in IFA on days 14, 28, and 42. One final dose in PBS was given 3 d. before fusion.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was obtained as described in Goodyear et al, J Clin Invest. 1999 104:697 [PMID:10491405].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-Intermediate</QualitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>EG1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG3</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27515</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>1953596</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:104</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>197</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Occurrence of autoimmune disease</InVivoProcessType>
                                <DiseaseState>DOID:12889</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Acute-phase serum samples obtained within one week of the onset of Miller-Fisher symptoms. Most of the patients had suffered a period of diarrhea during the weeks before the development of neurological symptoms, had immunoglobulin A (IgA) and/or IgM serum antibodies against a protein extract of C. jejuni, indicative of a recent infection, or had high-titer IgG anti-C. jejuni protein antibodies and a history of diarrhea.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>4</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:27515</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

